Latest News

LEO orders Hitgen to discover new leads

© LEO Pharma


by ml

In a multi-year collaboration with LEO Pharma A/S, Chinese Hitgen is poised to discover novel small molecule leads for multiple therapeutic targets chosen by the Danish skin treatment specialist.

A multi-year Danish-Chinese collaboration has been agreed upon in early August. Using its large DNA-encoded library of novel leads, Hitgen Ltd. of Chengdu will discover novel small molecule leads for multiple targets specified by LEO Pharma A/S, a Danish dermatology company based in Ballerup. Hitgen has established discovery partnerships with major global pharmas, including Janssen, Merck, Pfizer and the Scripps Research Institute. Under the terms of the LEO agreement, Hitgen will receive an upfront payment and be eligible for milestones. More specifically, Hitgen will use its advanced technology platform, based on DNA-encoded library design, synthesis and screening to discover novel leads which will be licensed exclusively to LEO Pharma. “We are excited by renewing and extending our collaboration with Hitgen” said Thorsten Thormann, Vice President of Research at LEO Pharma. “We are looking forward to expand our ability to identify new leads for multiple target families.“

© european-biotechnology.com/ml

Avantium NV bags money for demo plant

The new grant is part of a €30m financing mix that Avantium and the Groningen consortium announced this January. FDCA is the key building block for...

Swiss Noema Pharma raises CHF54m in Series A financing

It is one of the largest Series A rounds in Europe: Led by Sofinnova Partners and Polaris Partners, rare neurological diseases start-up Noema Pharma...

Siemens launches COVID-19 antigen lateral flow test

As testing capacities for the SARS-CoV-2 gold standard RT-PCR are going to be exhausted upon the looming second wave of infections with the novel...

Drug set to rescue COVID-19 patients at ICUs

Initial data from an US expanded access  (EA) use of RLF-100™ (aviptadil) in 90 ICU patients with critical COVID-19 and severe comorbidities...

Moderna to file for EU approval of mRNA-1273 vaccine

Modernas primary analysis of the COVE Phase III data was based on 196 cases, of which 185 cases of COVID-19 were observed in the placebo group versus...

Pfizer/BioNTech sign vaccine contract with EC

The deal includes an option for the European Commission to request an additional 100 million doses of BNT-162-b2. That's the largest initial order of...

BI initiates Phase II testing of COVID-19 drug

A new potential weapon against severe complications such as ARDS caused by the new coronavirus SARS-CoV-2 have been advanced by Boehringer Ingelheim...